文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

脂蛋白(a)和 ASCVD 风险预测的累积队列方程:动脉粥样硬化多民族研究。

Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis.

机构信息

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.

Section on Cardiovascular Medicine, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC, USA.

出版信息

Atherosclerosis. 2023 Sep;381:117217. doi: 10.1016/j.atherosclerosis.2023.117217. Epub 2023 Aug 9.


DOI:10.1016/j.atherosclerosis.2023.117217
PMID:37607461
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10659123/
Abstract

BACKGROUND AND AIMS: Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) but is not included in the Pooled Cohort Equations (PCE). We aimed to assess how well the PCE predict 10-year event rates in individuals with elevated Lp(a), and whether the addition of Lp(a) improves risk prediction. METHODS: We compared observed versus PCE-predicted 10-year ASCVD event rates, stratified by Lp(a) level and ASCVD risk category using Poisson regression, and evaluated the association between Lp(a) > 50 mg/dL and ASCVD risk using Cox proportional hazards models in the Multi-Ethnic Study of Atherosclerosis (MESA). We evaluated the C-index and net reclassification improvement (NRI) with addition of Lp(a) to the PCE. RESULTS: The study population included 6639 individuals (20%, n = 1325 with elevated Lp(a)). The PCE accurately predicted 10-year event rates for individuals with elevated Lp(a) with observed event rates falling within predicted limits. Elevated Lp(a) was associated with increased risk of CVD events overall (HR 1.27, 95% CI 1.00-1.60), particularly in low (HR 2.45, 95% CI 1.40-4.31), and high-risk (HR 1.41, 95% CI 1.02-1.96) individuals. Continuous NRI (95% CI) with the addition of Lp(a) to the PCE for CVD was 0.0963 (0.0158-0.1953) overall, and 0.2999 (0.0876, 0.5525) among low-risk individuals. CONCLUSIONS: The PCE performs well for event rate prediction in individuals with elevated Lp(a). However, Lp(a) is associated with increased CVD risk, and the addition of Lp(a) to the PCE improves risk prediction, particularly among low-risk individuals. These results lend support for increasing use of Lp(a) testing for risk assessment.

摘要

背景和目的:脂蛋白(a)[Lp(a)]是动脉粥样硬化性心血管疾病(ASCVD)的独立危险因素,但未包含在聚集队列方程(PCE)中。我们旨在评估 PCE 对 Lp(a)升高个体 10 年事件发生率的预测效果,以及添加 Lp(a)是否能改善风险预测。

方法:我们使用泊松回归比较了按 Lp(a)水平和 ASCVD 风险类别分层的观察到的与 PCE 预测的 10 年 ASCVD 事件发生率,并使用多民族动脉粥样硬化研究(MESA)中的 Cox 比例风险模型评估了 Lp(a)>50mg/dL 与 ASCVD 风险之间的关系。我们使用 PCE 中添加 Lp(a)的 C 指数和净重新分类改善(NRI)进行评估。

结果:研究人群包括 6639 名个体(20%,n=1325 名 Lp(a)升高)。PCE 准确地预测了 Lp(a)升高个体的 10 年事件发生率,观察到的事件发生率落在预测范围内。Lp(a)升高与 CVD 事件风险增加相关(HR 1.27,95%CI 1.00-1.60),尤其是在低危(HR 2.45,95%CI 1.40-4.31)和高危(HR 1.41,95%CI 1.02-1.96)个体中。将 Lp(a)添加到 PCE 后,CVD 的连续 NRI(95%CI)为 0.0963(0.0158-0.1953),在低危个体中为 0.2999(0.0876,0.5525)。

结论:PCE 对 Lp(a)升高个体的事件发生率预测效果良好。然而,Lp(a)与 CVD 风险增加相关,将 Lp(a)添加到 PCE 中可改善风险预测,尤其是在低危个体中。这些结果为增加 Lp(a)检测用于风险评估提供了支持。

相似文献

[1]
Lipoprotein(a) and the pooled cohort equations for ASCVD risk prediction: The Multi-Ethnic Study of Atherosclerosis.

Atherosclerosis. 2023-9

[2]
High-Sensitivity C-Reactive Protein Modifies the Cardiovascular Risk of Lipoprotein(a): Multi-Ethnic Study of Atherosclerosis.

J Am Coll Cardiol. 2021-9-14

[3]
Waist to hip ratio modifies the cardiovascular risk of lipoprotein (a): Insights from MESA.

Prog Cardiovasc Dis. 2025

[4]
First presentation of atherosclerotic cardiovascular disease in previously healthy individuals: The multi-ethnic study of atherosclerosis.

Prog Cardiovasc Dis. 2025-5-14

[5]
Performance of the Pooled Cohort Equations to Estimate Atherosclerotic Cardiovascular Disease Risk by Body Mass Index.

JAMA Netw Open. 2020-10-1

[6]
Lipoprotein(a) and Long-Term Cardiovascular Risk in a Multi-Ethnic Pooled Prospective Cohort.

J Am Coll Cardiol. 2024-4-23

[7]
Lipoprotein(a) in Youth and Prediction of Major Cardiovascular Outcomes in Adulthood.

Circulation. 2023-1-3

[8]
Lipoprotein(a) and Risk of Incident Atherosclerotic Cardiovascular Disease: Impact of High-Sensitivity C-Reactive Protein and Risk Variability Among Human Clinical Subgroups.

Nutrients. 2025-4-11

[9]
Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data.

Circ Genom Precis Med. 2025-2

[10]
Coronary Artery Calcium Scores and Atherosclerotic Cardiovascular Disease Risk Stratification in Smokers.

JACC Cardiovasc Imaging. 2018-2-14

引用本文的文献

[1]
Lipoprotein (a) in primary cardiovascular disease prevention is actionable today.

Am Heart J Plus. 2025-7-21

[2]
Prognostic value of lipoprotein(a) for cardiovascular events after lower limb revascularization in diabetic patients with chronic limb-threatening ischemia.

Cardiovasc Diabetol. 2025-7-10

[3]
AHA PREVENT Equations and Lipoprotein(a) for Cardiovascular Disease Risk : Insights From MESA and the UK Biobank.

JAMA Cardiol. 2025-6-4

[4]
Lipoprotein(a) Atherosclerotic Cardiovascular Disease Risk Score Development and Prediction in Primary Prevention From Real-World Data.

Circ Genom Precis Med. 2025-2

[5]
A Narrative Review of the Role of Blood Biomarkers in the Risk Prediction of Cardiovascular Diseases.

Cureus. 2024-12-1

[6]
Strategies for management of patients with elevated lipoprotein(a).

Curr Opin Lipidol. 2024-10-1

[7]
Lipoprotein(a) Levels in Disaggregated Racial and Ethnic Subgroups Across Atherosclerotic Cardiovascular Disease Risk Levels.

JACC Adv. 2024-5-2

[8]
Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy.

J Am Coll Cardiol. 2024-4-23

本文引用的文献

[1]
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society.

Atherosclerosis. 2023-6

[2]
Relationship of low-density lipoprotein-cholesterol and lipoprotein(a) to cardiovascular risk: The Multi-Ethnic Study of Atherosclerosis (MESA).

Atherosclerosis. 2022-12

[3]
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.

Eur Heart J. 2022-10-14

[4]
Independent Association of Lipoprotein(a) and Coronary Artery Calcification With Atherosclerotic Cardiovascular Risk.

J Am Coll Cardiol. 2022-3-1

[5]
Pooled Cohort Equations and the competing risk of cardiovascular disease versus cancer: Multi-Ethnic study of atherosclerosis.

Am J Prev Cardiol. 2021-6-14

[6]
2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.

Can J Cardiol. 2021-8

[7]
Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

N Engl J Med. 2020-1-1

[8]
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Eur Heart J. 2020-1-1

[9]
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

J Am Coll Cardiol. 2019-9-10

[10]
Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: The Atherosclerosis Risk in Communities study.

Atherosclerosis. 2018-12-30

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索